XML 50 R37.htm IDEA: XBRL DOCUMENT v3.3.1.900
Summarized Quarterly Data (Unaudited) (Tables)
 12 Months Ended
Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]  
Schedule of Quarterly Financial Information
Summarized quarterly data for the years ended December 31, 2015 and 2014 is as follows:
 
2015 Quarter Ended
 
March 31
 
June 30 (1)
 
September 30 (2)
 
December 31(3)
 
(in thousands, except per share amounts)
Revenue
$
4,614

 
$
7,367

 
$
9,120

 
$
6,081

Gross profit
$
691

 
$
1,564

 
$
1,340

 
$
1,231

Net loss from continuing operations
$
(10,165
)
 
$
(6,696
)
 
$
(12,981
)
 
$
(11,862
)
Net income (loss) from discontinued operations
$
(12,696
)
 
$
79,160

 
$
(1,635
)
 
$
3,019

Net income (loss)
$
(22,861
)
 
$
72,464

 
$
(14,616
)
 
$
(8,843
)
Net income (loss) per share, basic and diluted
$
(1.19
)
 
$
3.78

 
$
(0.65
)
 
$
(0.36
)

 
2014 Quarter Ended
 
March 31
 
June 30 (4)
 
September 30
 
December 31
 
(in thousands, except per share amounts)
Revenue
$
7,389

 
$
6,737

 
$
4,883

 
$
9,938

Gross profit
$
4,056

 
$
2,874

 
$
897

 
$
1,515

Net income (loss) from continuing operations
$
(4,952
)
 
$
77,536

 
$
(1,461
)
 
$
(9,636
)
Net loss from discontinued operations
$
(15,980
)
 
$
(14,672
)
 
$
(11,364
)
 
$
(10,884
)
Net income (loss)
$
(20,932
)
 
$
62,864

 
$
(12,825
)
 
$
(20,520
)
Net income (loss) per share, basic
$
(1.20
)
 
$
3.59

 
$
(0.73
)
 
$
(1.09
)
Net income (loss) per share, diluted
$
(1.61
)
 
$
3.59

 
$
(0.73
)
 
$
(1.09
)


(1) Net income from discontinued operations includes a gain on sale of Zohydro ER business of $75,575,000. Net income (loss) from continuing operations includes a tax benefit related to the sale of Zohydro ER of $6,946,000.

(2) Net loss from continuing operations includes an impairment charge on investments acquired in conjunction with the sale of the Zohydro ER business of $5,485,000 and tax benefit related to the sale of the Zohydro ER business of $5,496,000. Net income (loss) from discontinued operations includes a reduction of the gain on sale of Zohydro ER business of $2,474,000 which is comprised primarily of the recognition of additional income tax expense for the period.
 
(3) Net loss from continuing operations includes a tax benefit related to the sale of Zohydro ER of $3,472,000. Net income (loss) from discontinued operations includes an increase of the gain on sale of Zohydro ER business of $2,323,000 which is comprised primarily of the recognition of contingent consideration of $385,000 and derecognition of income tax liability for the period based on reduction in applicable tax rate.

(4) Net income from continuing operations includes the one-time gain on sale of the Sumavel DosePro business of $79,980,000, a one-time charge for extinguishment of debt of $1,254,000 incurred in connection with termination of Healthcare Royalty Financing Agreement, and an impairment charge on long lived assets related to sale of Sumavel DosePro business of $838,000.